Key Events This Week
16 Mar: Stock hits 52-week low near Rs.330.05 amid continued downtrend
19 Mar: Valuation shifts from expensive to fair as sector volatility persists
20 Mar: Week closes at Rs.332.95, down 5.68% for the week
Apr 30
BSE+NSE Vol: 55.52 k

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend. Despite a modest 1.05% gain in the latest session, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum tools, prompting a downgrade to a Strong Sell rating by MarketsMOJO as of 3 Nov 2025.
Read full news article
FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 April 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Despite a broadly recovering market, FDC Ltd has slipped to a fresh 52-week low of Rs 314.75 on 30 Mar 2026, marking a continuation of its recent downward trajectory with a 3-day losing streak and a 3.8% decline over this period.
Read full news article
16 Mar: Stock hits 52-week low near Rs.330.05 amid continued downtrend
19 Mar: Valuation shifts from expensive to fair as sector volatility persists
20 Mar: Week closes at Rs.332.95, down 5.68% for the week

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 29 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
While the broader market has shown signs of recovery, FDC Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 318.1 on 27 Mar 2026. This decline comes amid a backdrop of underwhelming financial performance and waning institutional support, raising questions about the stock’s near-term outlook.
Read full news articleFDC Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
FDC Limited has informed the Exchange regarding 'Acquisition of Registered Trademark/ Brand "ENTEROPLUS" from GlaxoSmithKline Pharmaceuticals Limited (GSK)'.
FDC Limited has informed the Exchange regarding 'Certificate in terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ( said regulations ) on behalf of FDC Limited ( the Company ) for the quarter ended on September 30, 2019'.'.
No Upcoming Board Meetings
FDC Ltd has declared 500% dividend, ex-date: 11 Feb 26
No Splits history available
No Bonus history available
No Rights history available